Skip to Content

Intarcia Announces Branding of the Medici Drug Delivery System™ – A Platform of Technologies Key to Advancing its Pipeline of Once-Yearly Peptide and Antibody Fragment-Based Therapeutics in Poorly Controlled Chronic Diseases

Intarcia Announces Branding of the Medici Drug Delivery System™ – A Platform of Technologies Key to Advancing its Pipeline of Once-Yearly Peptide and Antibody Fragment-Based Therapeutics in Poorly Controlled Chronic Diseases

  • The Medici Drug Delivery System is a proprietary subcutaneous delivery system comprised of three unique technologies: osmotic mini-pump technology; mini-pump placement technology; and our high temperature therapeutic stabilization technology
  • Each osmotic mini-pump is designed to hold an appropriate volume of therapeutics, both mono and combination therapies, to treat a patient for up to a full year. One of the unique aspects of the System is the stabilization technology – proteins, peptides, antibody fragments, and other highly-potent small molecules may be stabilized at or above human body temperatures for up to three years or more
  • Intarcia Therapeutics is currently researching products, including combination products, that may be used with the Medici Drug Delivery System to potentially treat chronic conditions such as diabetes, obesity, autoimmune, and other serious diseases

Boston, MA – June 7, 2016 – Intarcia Therapeutics, Inc. introduced today the Medici Drug Delivery System, its innovative proprietary subcutaneous delivery system, comprised of three unique technologies: a matchstick-sized osmotic mini-pump that is placed just beneath the skin to deliver a continuous and consistent flow of medication; a placement technology designed for a simple, relatively quick and highly reliable user experience; and a stabilization technology for proteins, peptides, antibody fragments, and other high-potency small molecules. The System will be on display later this month at the American Diabetes Association’s 76th Scientific Sessions in New Orleans.

“Delivering drugs via our new technology has the potential to open up a new way of delivering novel medicines just once-yearly,” said Kurt Graves, Chairman, President and CEO of Intarcia. “One of the biggest problems in chronic diseases is millions of patients lack effective control of their condition due to sub-optimal effectiveness of their medication, and the fact is, the majority of patients with chronic conditions stop taking these pills and injections, after just three-to-six months. We are aiming to address these serious and costly unmet needs by introducing a new way to deliver once-yearly therapies that hold the potential for game-changing improvements in outcomes and patient adherence over time. We believe that our novel technology platform, the Medici Drug Delivery System, represents the potential for a renaissance in medicine delivery for the treatment of major chronic diseases.”

The osmotic mini-pump can be quickly and simply placed by a trained physician, physician assistant, or nurse practitioner. Once placed just beneath the skin, water from the extracellular fluid enters the pump device at one end – by diffusing through a semi-permeable membrane directly into a salt osmotic engine – that expands to drive a piston at a controlled rate. This forces the drug within the pump to be released in a steady, consistent fashion at the distal end of the device.

Each osmotic mini-pump is designed to hold an appropriate volume of drug product to treat a patient for a predetermined extended duration of time. One of the unique aspects of the System is the stabilization technology – proteins, peptides, antibody fragments, and other high-potency small molecules may be stabilized at or above human body temperatures for extended periods of time.

The Medici Drug Delivery System has the potential to be used in chronic conditions such as diabetes, obesity, autoimmune, and other serious diseases. Intarcia is currently researching new therapies, including combination products, to use within its drug delivery technology (proteins, peptides, antibody fragments, and other high-potency small molecules).

About Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to enhance treatment outcomes by optimizing and improving the efficacy, continuous administration and tolerability of drug therapies. Delivering medicines for up to a year and beyond has the potential to ensure improved patient adherence and compliance, which is very poor in most chronic diseases. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins, peptides, antibody fragments, and other high-potency small molecules at or above body temperature, and to deliver them in a constant and consistent manner via Intarcia's proprietary technology platform, the Medici Drug Delivery System. Intarcia continues to conduct research and development, utilizing its platform technology, to treat other chronic, serious disorders such as diabetes, obesity, autoimmune, and other serious diseases. For more information on the Company, please visit www.intarcia.com.

Intarcia and its logo are registered trademarks of Intarcia Therapeutics, Inc.

 

INVESTOR CONTACT

Intarcia Therapeutics, Inc.
James Ahlers
james.ahlers@intarcia.com
(510) 782-7800

MEDIA CONTACTS

Intarcia Therapeutics, Inc.
Paulina Bucko
paulina.bucko@intarcia.com
(857) 880-1442

Shaping the future:

Press Releases

Intarcia Appoints Thane Wettig as Chief Marketing Officer and Metabolic Franchise Head

Read More

Intarcia Provides Corporate Update

Read More

Intarcia Strengthens Board of Directors for Next Stage of Growth

Read More
MORE NEWS
Back to top